Viridian Therapeutics (VRDN) AI Stock Analysis

• Market Cap: $2.10B
• Dividend Yield: N/A
• Average Volume (3M): 814.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.63
• Revenue Growth: 5.90%
• EPS Growth: -0.36%
• Country: US
• Employees: 143
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.00
• Shares Outstanding: 93,093,030
• 10 Day Avg. Volume: 1,087,693
• 30 Day Avg. Volume: 814,586
• PEG Ratio: 0.19
• Price to Book (P/B): 1.94
• Price to Sales (P/S): 4309.19
• P/FCF Ratio: -5.59
• Enterprise Value/Market Cap: 0.38
• Enterprise Value/Revenue: 11.15
• Enterprise Value/Gross Profit: 8.22K
• Enterprise Value/Ebitda: -2.59
• 1Y Price Target: $39.18
• Price Target Upside: 60.44% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $24.50 ▲(0.33% Upside)

Viridian Therapeutics' overall stock score is primarily impacted by its weak financial performance, characterized by persistent losses and cash flow challenges. Despite these financial difficulties, the stock shows positive technical momentum, which provides some optimism. However, the negative P/E ratio and lack of dividend yield weigh down the valuation score, reflecting the company's ongoing financial struggles.

Positive Factors

Regulatory Progress

The BLA submission for veligrotug marks a significant regulatory milestone. If approved, it could lead to a commercial launch by mid-2026, enhancing Viridian's market position in treating thyroid eye disease.

Financial Strengthening

Recent financial maneuvers, including equity raises and royalty financing, have strengthened Viridian's balance sheet, providing resources to support its path to profitability and long-term growth.

Product Pipeline Advancements

Progress in clinical trials for VRDN-003 and FcRn programs indicates a robust pipeline, potentially leading to new product approvals and revenue streams, reinforcing Viridian's long-term growth prospects.

Negative Factors

Profitability Challenges

Ongoing profitability issues, with persistent losses and negative cash flows, threaten Viridian's financial sustainability, requiring careful management to avoid long-term financial distress.

Cash Flow Weakness

Negative cash flows highlight inefficiencies in converting income into cash, posing risks to Viridian's ability to fund operations and invest in growth without external financing.

Negative Profit Margins

Negative profit margins indicate ongoing operational challenges, limiting Viridian's ability to generate sustainable profits and necessitating strategic changes to improve financial performance.

Viridian Therapeutics Business Overview & Revenue Model

Company Description

Viridian Therapeutics, Inc. (VRDN) is a biotechnology company focused on developing innovative therapies for patients with serious diseases, particularly in the field of ophthalmology and autoimmune disorders. The company leverages its proprietary technology platforms to design and produce monoclonal antibodies and other biologics that address unmet medical needs. With a commitment to advancing the science of therapeutic development, Viridian aims to deliver transformative treatments to improve patient outcomes.

How the Company Makes Money

Viridian Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company may earn money through several key revenue streams, including product sales from approved therapies, milestone payments from partnerships with larger pharmaceutical companies, and potential royalties on future product sales. Significant partnerships with larger biopharmaceutical firms can provide additional financial resources and support for research and development efforts, enhancing the company's ability to bring products to market. Additionally, Viridian may also receive funding through grants or investments aimed at supporting its clinical trials and drug development initiatives.

Viridian Therapeutics Financial Statement Overview

Summary

Viridian Therapeutics is struggling with profitability and cash flow generation, which are critical for its sustainability. The company has persistent losses, negative cash flows, and a negative return on equity, posing significant risks despite a low leverage position.

Income Statement

Viridian Therapeutics shows significant challenges in its income statement. The company has experienced negative net profit margins and EBIT margins over the years, indicating persistent losses. Although there was a slight revenue growth in the TTM period, the overall trajectory has been volatile with significant declines in previous years. The gross profit margin has been positive in recent periods, but the high negative net profit margin remains a concern.

Balance Sheet

The balance sheet of Viridian Therapeutics reflects a relatively low debt-to-equity ratio, suggesting limited leverage, which is a positive aspect. However, the return on equity is negative, indicating that the company is not generating profit from its equity base. The equity ratio is stable, but the overall financial health is hindered by the lack of profitability.

Cash Flow

Cash flow analysis reveals that Viridian Therapeutics is facing challenges with negative operating and free cash flows, indicating cash burn. Although there was a slight improvement in free cash flow growth in the TTM period, the overall cash flow situation remains weak. The operating cash flow to net income ratio is negative, highlighting inefficiencies in converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	70.79M	302.00K	314.00K	1.77M	2.96M	1.05M
Gross Profit	96.00K	302.00K	-1.01M	1.02M	2.34M	-27.25M
EBITDA	-305.07M	-265.66M	-234.56M	-128.63M	-78.79M	-109.67M
Net Income	-301.97M	-269.95M	-237.73M	-125.44M	-79.42M	-110.98M
Balance Sheet
Total Assets	577.14M	742.40M	490.42M	435.09M	203.71M	131.25M
Cash, Cash Equivalents and Short-Term Investments	490.90M	717.58M	477.37M	424.55M	196.97M	127.64M
Total Debt	20.89M	21.09M	21.05M	5.26M	520.00K	455.00K
Total Liabilities	74.17M	70.76M	48.40M	40.03M	15.99M	11.22M
Stockholders Equity	502.97M	671.64M	442.02M	395.06M	187.72M	120.04M
Cash Flow
Free Cash Flow	-326.34M	-232.83M	-185.07M	-94.64M	-54.92M	-29.82M
Operating Cash Flow	-325.97M	-232.32M	-184.17M	-93.84M	-54.58M	-29.78M
Investing Cash Flow	238.94M	-228.65M	-94.25M	-115.13M	-74.29M	-50.48M
Financing Cash Flow	56.36M	457.74M	225.67M	322.24M	125.28M	101.31M

Viridian Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 24.42
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VRDN, the sentiment is Positive. The current price of 24.42 is above the 20-day moving average (MA) of 22.74, above the 50-day MA of 20.95, and above the 200-day MA of 16.88, indicating a bullish trend. The MACD of 0.75 indicates Positive momentum. The RSI at 63.40 is Neutral, neither overbought nor oversold. The STOCH value of 61.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VRDN.

Viridian Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JANX	55 Neutral	$1.62B	-15.33	-12.82%	―	-97.10%	-96.30%
VRDN	52 Neutral	$2.10B	-5.29	-62.99%	―	5.90%	-0.36%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DNTH	44 Neutral	$1.32B	-10.20	-34.71%	―	17.87%	41.27%
PHVS	42 Neutral	$1.39B	―	-63.96%	―	―	-36.92%
EWTX	40 Underperform	$1.83B	―	-27.41%	―	―	-1.46%
BHVN	40 Underperform	$1.48B	―	-295.94%	―	―	16.36%

Viridian Therapeutics Corporate Events

Viridian Therapeutics’ Promising Phase 3 Trial for Thyroid Eye Disease

Viridian Therapeutics, Inc. is conducting a Phase 3 clinical trial titled ‘A Randomized, Open-label Study Evaluating the Safety, Tolerability and Pharmacokinetics of VRDN-003 Administered Subcutaneously in Participants With Thyroid Eye Disease (TED).’ The study aims to assess the safety, tolerability, and pharmacokinetics of VRDN-003, a humanized monoclonal antibody targeting the IGF-1 receptor, in individuals with Thyroid Eye Disease. This trial is significant as it could offer a new therapeutic option for TED, a condition with limited treatment options.

Viridian Therapeutics Advances VRDN-003 Study for Thyroid Eye Disease

Viridian Therapeutics, Inc. is conducting a clinical study titled A Randomized, Double-masked, Controlled, Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED). The study aims to evaluate the safety and tolerability of VRDN-003, a potential treatment for TED, a condition that affects the eyes of people with thyroid disorders. This study is significant as it could lead to a new therapeutic option for TED patients.

Viridian Therapeutics Announces Stock Sale Agreement

On October 21, 2025, Viridian Therapeutics announced an underwriting agreement for the sale of 11,425,000 shares of common stock at $22.00 per share, potentially raising approximately $251.35 million. The proceeds, combined with other financial resources, are expected to fund the company’s operations, including anticipated revenue from product sales and milestone payments, although the company acknowledges potential risks and uncertainties in its financial projections.

The most recent analyst rating on (VRDN) stock is a Hold with a $24.50 price target. To see the full list of analyst forecasts on Viridian Therapeutics stock, see the VRDN Stock Forecast page.

Viridian Therapeutics Secures $300M Deal with DRI Healthcare

On October 17, 2025, Viridian Therapeutics entered into a Purchase and Sale Agreement with DRI Healthcare Acquisitions, selling rights to certain revenue streams in the U.S. for up to $300 million. This agreement includes payments contingent on achieving specific clinical and regulatory milestones for its products VRDN-003 and veligrotug. Additionally, Viridian amended its Loan and Security Agreement with Hercules Capital, securing a new term loan facility of up to $300 million, structured in tranches contingent on regulatory and revenue milestones, with a maturity date set for October 17, 2030.

The most recent analyst rating on (VRDN) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Viridian Therapeutics stock, see the VRDN Stock Forecast page.

Viridian Therapeutics Reports Q2 2025 Financial Results

Viridian Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases, with a primary focus on thyroid eye disease and autoimmune conditions.